# AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

> **NCT00126880** · PHASE2 · COMPLETED · sponsor: **Avexa** · enrollment: 52 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** AVX754
- **DRUG:** 3TC

## Key facts

- **NCT ID:** NCT00126880
- **Lead sponsor:** Avexa
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126880, "AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00126880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*